phrykt

Roivant Sciences Ltd. (ROIV): who owns it and who trades it

As of Nov 16, 2026, ROIV insiders reported 83 open-market sales worth $594M and no purchases in the last 12 months, with 25% of the sale value made under pre-set 10b5-1 plans. The largest seller was Keith S Manchester (Director), with $115M. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Roivant Sciences

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ROIV

497 funds and institutions reported ROIV shares worth $20.6B at the end of Q2 2026, about 81% of the company. The largest holder is FMR LLC (Fidelity) with 11.3%.

Funds and institutions (13F) 81%Everyone else 19%

10 largest owners, by share of the company

FMR LLC (Fidelity)11.3%
BlackRock, Inc.6.7%
Morgan Stanley5.9%
QVT Financial LP3.3%
Vanguard Capital Management LLC3.1%
Vanguard Portfolio Management LLC3.0%
California State Teachers Retirement System2.6%
Goldman Sachs Group Inc2.6%
State Street Corp2.5%
UBS Group AG2.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)81.02M11.26%$2.9B+4%
BlackRock, Inc.48.24M6.71%$1.7B+9%
Morgan Stanley42.59M5.92%$1.5B-18%
QVT Financial LP23.72M3.30%$840M-6%
Vanguard Capital Management LLC22.12M3.08%$783M+7%
Vanguard Portfolio Management LLC21.64M3.01%$766M+9%
California State Teachers Retirement System19.00M2.64%$537M+4212%
Goldman Sachs Group Inc18.56M2.58%$657M+67%
State Street Corp17.80M2.47%$630M+10%
UBS Group AG17.47M2.43%$618M-23%
Assenagon Asset Management S.A.16.73M2.33%$592M+136%
Farallon Capital Management, L.l.c.14.31M1.99%$506M+48%
Geode Capital Management, LLC11.67M1.62%$426M+15%
Adage Capital Partners Gp, L.l.c.10.35M1.44%$366M-19%
Two Seas Capital LP8.48M1.18%$300M-9%
Perceptive Advisors LLC8.09M1.12%$286M-2%
Patient Square Capital LP8.02M1.12%$284M-2%
Invesco Ltd.7.53M1.05%$267M+17%
Darwin Global Management, Ltd.6.75M0.94%$234M-1%
AQR Capital Management LLC6.63M0.92%$234M+12%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ROIV insiders reported $0 of open-market purchases and $594M of sales. 25% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$594M
83 trades, 11 people
Sales under a 10b5-1 plan
25%
Share of sale value
Latest trade
Nov 11, 2026
Filed Nov 12, 2026

Purchases and sales by month

$194M$194MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 11, 2026Richard PulikCFOSale45,195$41.47$1.9MForm 4
Nov 11, 2026Richard PulikCFOSale82,170$42.03$3.5MForm 4
Nov 11, 2026Richard PulikCFOSale47,635$41.89$2MForm 4
Nov 10, 2026Richard PulikCFOSale125,000$41.20$5.2MForm 4
Nov 10, 2026Eric VenkerCEOSale plan158,194$40.44$6.4MForm 4
Nov 10, 2026Eric VenkerCEOSale plan29,749$41.00$1.2MForm 4
Nov 3, 2026Eric VenkerCEOSale plan200,000$36.31$7.3MForm 4
Oct 28, 2026Eric VenkerCEOSale plan200,000$36.59$7.3MForm 4
Oct 20, 2026Eric VenkerCEOSale plan185,856$35.09$6.5MForm 4
Oct 20, 2026Eric VenkerCEOSale plan14,144$35.42$501KForm 4
Oct 1, 2026Melissa B EpperlyDirectorSale plan16,850$36.08$608KForm 4
Oct 1, 2026Melissa B EpperlyDirectorSale plan900$36.57$32.9KForm 4
Sep 30, 2026Eric VenkerCEOSale plan200,000$36.62$7.3MForm 4
Sep 15, 2026Melissa B EpperlyDirectorSale plan4,338$39.65$172KForm 4
Sep 15, 2026Melissa B EpperlyDirectorSale plan600$40.38$24.2KForm 4
Sep 15, 2026Meghan FitzgeraldDirectorSale plan400$40.45$16.2KForm 4
Sep 15, 2026Meghan FitzgeraldDirectorSale plan4,712$39.68$187KForm 4
Sep 8, 2026Meghan FitzgeraldDirectorSale20,000$39.90$798KForm 4
Aug 28, 2026Eric VenkerCEOSale166,182$35.63$5.9MForm 4
Aug 28, 2026Eric VenkerCEOSale33,818$36.44$1.2MForm 4
Aug 21, 2026Mayukh SukhatmePresidentSale144,756$36.48$5.3MForm 4
Aug 20, 2026Mayukh SukhatmePresidentSale17,519$37.30$653KForm 4
Aug 19, 2026Mayukh SukhatmePresidentSale172,899$37.17$6.4MForm 4
Aug 18, 2026Mayukh SukhatmePresidentSale105,141$36.59$3.8MForm 4
Aug 18, 2026Mayukh SukhatmePresidentSale31,801$37.18$1.2MForm 4
Aug 17, 2026Mayukh SukhatmePresidentSale284,707$36.25$10.3MForm 4
Aug 14, 2026Mayukh SukhatmePresidentSale243,177$36.23$8.8MForm 4
Jul 27, 2026Eric VenkerCEOSale200,000$34.95$7MForm 4
Jun 30, 2026Meghan FitzgeraldDirectorSale plan10,000$34.90$349KForm 4
Jun 30, 2026Keith S ManchesterDirectorSale200,000$35.45$7.1MForm 4
Jun 30, 2026Keith S ManchesterDirectorSale12,380$35.28$437KForm 4
Jun 29, 2026Melissa B EpperlyDirectorSale plan2,748$34.71$95.4KForm 4
Jun 29, 2026Melissa B EpperlyDirectorSale plan15,002$34.32$515KForm 4
Jun 29, 2026Keith S ManchesterDirectorSale600,000$34.59$20.8MForm 4
Jun 29, 2026Keith S ManchesterDirectorSale200,000$34.44$6.9MForm 4
Jun 26, 2026Keith S ManchesterDirectorSale325,000$34.07$11.1MForm 4
Jun 26, 2026Keith S ManchesterDirectorSale300,783$33.92$10.2MForm 4
Jun 26, 2026Mayukh SukhatmePresidentSale500,000$34.08$17MForm 4
Jun 25, 2026Mayukh SukhatmePresidentSale500,000$34.13$17.1MForm 4
Jun 24, 2026Eric VenkerCEOSale plan46,234$33.51$1.5MForm 4
Jun 24, 2026Eric VenkerCEOSale plan153,766$33.05$5.1MForm 4
May 22, 2026Eric VenkerCEOSale plan200,000$30.27$6.1MForm 4
Apr 20, 2026Eric VenkerCEOSale plan200,000$29.59$5.9MForm 4
Apr 16, 2026Matthew GlineCEOSale289,774$29.16$8.4MForm 4
Apr 8, 2026Jennifer HumesChief Accounting OfficerSale13,538$28.37$384KForm 4
Mar 26, 2026Meghan FitzgeraldDirectorSale70,000$27.45$1.9MForm 4
Mar 17, 2026Eric VenkerCEOSale plan200,000$28.24$5.6MForm 4
Mar 16, 2026Melissa B EpperlyDirectorSale41,861$28.68$1.2MForm 4
Feb 23, 2026Frank TortiPresidentSale plan587,390$27.51$16.2MForm 4
Feb 20, 2026Frank TortiPresidentSale plan1.01M$27.15$27.5MForm 4
Feb 19, 2026Frank TortiPresidentSale plan1.40M$27.42$38.4MForm 4
Feb 13, 2026Eric VenkerCEOSale plan200,000$26.49$5.3MForm 4
Feb 13, 2026Keith S ManchesterDirectorSale150,784$26.49$4MForm 4
Feb 13, 2026Keith S ManchesterDirectorSale225,000$26.50$6MForm 4
Feb 12, 2026Keith S ManchesterDirectorSale275,000$26.76$7.4MForm 4
Feb 12, 2026Keith S ManchesterDirectorSale150,000$26.72$4MForm 4
Feb 11, 2026Keith S ManchesterDirectorSale425,000$26.67$11.3MForm 4
Feb 9, 2026Mayukh SukhatmePresidentSale339,441$26.47$9MForm 4
Jan 12, 2026Eric VenkerCEOSale200,000$21.92$4.4MForm 4
Dec 31, 2025Mayukh SukhatmePresidentSale1.02M$21.71$22.1MForm 4
Dec 29, 2025Mayukh SukhatmePresidentSale311,873$21.74$6.8MForm 4
Dec 24, 2025Eric VenkerCEOSale75,000$22.53$1.7MForm 4
Dec 23, 2025Richard PulikCFOSale146,731$22.39$3.3MForm 4
Dec 23, 2025Richard PulikCFOSale260,000$22.45$5.8MForm 4
Dec 23, 2025Eric VenkerCEOSale200,000$22.45$4.5MForm 4
Dec 17, 2025Mayukh SukhatmePresidentSale26,831$23.09$620KForm 4
Dec 17, 2025Daniel Allen GoldDirectorSale189,538$23.17$4.4MForm 4
Dec 17, 2025Daniel Allen GoldDirectorSale155,076$23.02$3.6MForm 4
Dec 17, 2025Daniel Allen GoldDirectorSale432,718$23.05$10MForm 4
Dec 16, 2025Daniel Allen GoldDirectorSale642,282$23.08$14.8MForm 4
Dec 16, 2025Daniel Allen GoldDirectorSale275,000$22.93$6.3MForm 4
Dec 15, 2025Matthew GlineCEOSale943,527$21.68$20.5MForm 4
Dec 15, 2025Matthew GlineCEOSale230,357$21.68$5MForm 4
Dec 15, 2025Matthew GlineCEOSale566,116$21.68$12.3MForm 4
Dec 15, 2025Vivek Ramaswamy10% ownerSale353,745$22.05$7.8MForm 4
Dec 12, 2025Vivek Ramaswamy10% ownerSale1.98M$21.96$43.4MForm 4
Dec 11, 2025Vivek Ramaswamy10% ownerSale774,142$21.64$16.8MForm 4
Dec 9, 2025Eric VenkerCEOSale200,000$20.85$4.2MForm 4
Nov 19, 2025Keith S ManchesterDirectorSale850,000$20.25$17.2MForm 4
Nov 19, 2025Keith S ManchesterDirectorSale150,000$20.20$3MForm 4
Nov 19, 2025Keith S ManchesterDirectorSale125,000$20.16$2.5MForm 4
Nov 19, 2025Keith S ManchesterDirectorSale175,000$20.24$3.5MForm 4
Nov 17, 2025Vivek Ramaswamy10% ownerSale539,650$20.51$11.1MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Keith S ManchesterDirector–$115MJun 30, 2026
Mayukh SukhatmePresident & CIO, Director–$109MAug 21, 2026
Eric VenkerPresident & Immunovant CEO–$95MNov 10, 2026
Frank TortiPresident and Vant Chair–$82MFeb 23, 2026
Vivek Ramaswamy10% owner–$79MDec 15, 2025
Matthew GlineCEO, Director–$46.2MApr 16, 2026
Daniel Allen GoldDirector–$39.1MDec 17, 2025
Richard PulikCFO–$21.6MNov 11, 2026
Meghan FitzgeraldDirector–$3.3MSep 15, 2026
Melissa B EpperlyDirector–$2.6MOct 1, 2026
Jennifer HumesChief Accounting Officer–$384KApr 8, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ROIV short interest

Moderate short interest. 6.3% of ROIV shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went up 66%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 45.51M ROIV shares were sold short, 6.3% of the shares outstanding, up 12.9% from the report before. At the average daily volume of 7.50M shares, buying them all back would take about 6.1 trading days (days to cover).

Shares short, % of all shares

6.30%May 15Oct 306.68%

Days to cover

6.1May 15Oct 308.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202645.51M6.30%+13%7.50M6.1
Oct 15, 202640.30M5.58%+3%5.11M7.9
Sep 30, 202639.30M5.44%+9%8.88M4.4
Sep 15, 202636.18M5.01%+8%8.75M4.1
Aug 31, 202633.52M4.64%+10%8.76M3.8
Aug 14, 202630.60M4.24%-13%6.10M5.0
Jul 31, 202635.23M4.88%-4%4.41M8.0
Jul 15, 202636.70M5.10%+10%4.80M7.7
Jun 30, 202633.21M4.62%-0%7.78M4.3
Jun 15, 202633.24M4.62%-8%4.42M7.5
May 29, 202636.23M5.04%+32%8.75M4.1
May 15, 202627.38M3.81%+1%4.81M5.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded ROIV

Since Nov 17, 2024, 1 member of Congress reported 2 purchases and 2 sales of ROIV. The latest was a sale by Lisa C. McClain on Oct 31, 2025, reported Nov 21, 2025.

Purchases 2Sales 2

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Oct 31, 2025Lisa C. McClain (R-MI)Sale$1K–$15KSpouseNov 21, 2025Report
Oct 30, 2025Lisa C. McClain (R-MI)Sale$1K–$15KSpouseNov 21, 2025Report
Oct 30, 2025Lisa C. McClain (R-MI)Purchase$1K–$15KSpouseNov 21, 2025Report
Jun 17, 2025Lisa C. McClain (R-MI)Purchase$1K–$15KSpouseAug 13, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Roivant Sciences company events

Roivant Sciences filed 14 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Oct 21, 2026AnnouncementShared information with investors. Filing
  3. Sep 18, 2026VoteReported shareholder vote results. Filing
  4. Sep 8, 2026AnnouncementShared information with investors. Filing
  5. Aug 28, 2026AnnouncementRoivant Sciences Ltd. posted a presentation regarding the approval by the U.S. Food and Drug Administration of LISRAYA™ (brepocitinib) for the treatment of adults with dermatomyositis on the “Events & Presentations” page of its investor relations website at investor.roivant.com. Filing
  6. Aug 27, 2026AnnouncementShared information with investors. Filing
  7. Aug 6, 2026ResultsReleased financial results. Filing
  8. May 20, 2026ResultsReleased financial results. Filing
  9. Apr 2, 2026ResultsReleased financial results. Filing
  10. Mar 23, 2026AgreementAmended an earlier report. Of the Original 8-K, which indicated that a copy of the Settlement Agreement would be filed as an exhibit to a subsequent filing with the SEC. Except as set forth herein, no other changes have been made to the Original 8-K, and this Amendment does not modify or update any other disclosures set… Filing
  11. Mar 3, 2026AgreementGenevant Sciences GmbH, a subsidiary of Roivant Sciences Ltd., Arbutus Biopharma Corp. (together with Genevant, “Genevant/Arbutus”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement to resolve… Filing
  12. Mar 3, 2026AnnouncementShared information with investors. Filing
  13. Feb 6, 2026ResultsReleased financial results. Filing
  14. Dec 11, 2025AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Roivant Sciences financials

Famous investors that hold ROIV

6 of the 50 well-known investors we track reported holding ROIV in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $247M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Andreas Halvorsen · Viking Global InvestorsQ3 20266.76M$247M0.8%+8%
Steve Cohen · Point72 Asset ManagementQ3 20264.82M$176M0.3%+8%
Lee Ainslie · Maverick CapitalQ3 20262.31M$84.4M0.7%-18%
David Einhorn · Greenlight Capital (DME)Q3 20261.13M$41.4M1.2%-47%
Ken Griffin · Citadel AdvisorsQ3 2026962,603$35.2M0.0%-83%
Ken Fisher · Fisher Asset ManagementQ3 202613,597$497K0.0%-14%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ROIV in the last 120 days.

FiledHolderFormStake
Nov 5, 2026FMR LLC13G/A11.8%
Nov 5, 2026FMR LLC13G/A11.8%
Oct 27, 2026BlackRock, Inc.13G/A8.2%
Oct 27, 2026BlackRock, Inc.13G/A8.2%

Questions about Roivant Sciences Ltd. (ROIV) stock

Who owns the most ROIV stock?

The largest reported owner of Roivant Sciences Ltd. (ROIV) is FMR LLC (Fidelity), with 11.3% of the company. In total, 497 funds and institutions reported holding ROIV at the end of Q2 2026, together about 81% of the shares. See the largest owners.

Are ROIV insiders buying or selling?

In the last 12 months, ROIV insiders reported no open-market purchases and 83 sales worth $594M. The latest trade was on Nov 11, 2026. See every trade.

What is the short interest in ROIV?

As of Oct 30, 2026, 45.51M ROIV shares were sold short, 6.3% of the shares outstanding, up 12.9% from the report before. At the average daily volume of 7.50M shares, buying them all back would take about 6.1 trading days (days to cover). See the history.

Have members of Congress traded ROIV?

Yes. 1 member of Congress reported 2 purchases and 2 sales of ROIV since Nov 17, 2024. The latest was reported on Nov 21, 2025. See the trades.

Which famous investors hold ROIV?

6 of the 50 well-known investors we track reported ROIV in their latest 13F filing, including Andreas Halvorsen, Steve Cohen, Lee Ainslie. The largest position is worth $247M. See all holders.

Executive pay

Roivant Sciences's chief executive was paid a total of $3.1M for the year ended Mar 31, 2026, down 98% from $163M the year before. In the last 12 months, Roivant Sciences's executives and directors bought no stock on the open market and sold $515M.

Chief executive, total pay$3.1MYear ended Mar 31, 2026. Salary, bonus and the value of stock and option awards when granted.
Other top executives, average$38.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.